Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 15/20 | 0.71 |
| ▸ | PI4K2B | Q8TCG2 | 15/20 | 0.71 |
| ▸ | PI4K2A | Q9BTU6 | 15/20 | 0.71 |
| ▸ | PI4KB | Q9UBF8 | 15/20 | 0.71 |
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.53 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.42 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25311191 | 0.90 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL25311189 | 0.90 | PI4KA (0.65) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL3538512 | 0.86 | PI4KA (0.77) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL23869832 | 0.84 | PI4KA (0.52) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL21638051 | 0.83 | PI4KA (0.72) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL25311025 | 0.81 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL25311020 | 0.81 | PI4KA (0.56) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL23291064 | 0.80 | PI4KA (0.72) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL5146335 | 0.80 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR | |
| SCHEMBL23869679 | 0.79 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210299095-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | CASE WESTERN RESERVE UNIVERSITY | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210299095-A1 | METHOD OF MODULATING RIBONUCLEOTIDE REDUCTASE | RRM2, RRM2B, RRM1 | PI4KA 3742/4885PI4K2B 3616/4885PI4K2A 3418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.